A. Oliver Sartor

Oliver Sartor is a world authority on prostate cancer bone metastasis and led the ALSYMPCA trial establishing radium-223 dichloride as the first alpha-particle therapy to demonstrate an overall survival benefit in cancer. His research on alpha-particle therapy opened an entirely new category of bone-targeted radiopharmaceuticals. He has contributed to understanding the biology of prostate cancer bone tropism and developed multiple clinical trials combining radium-223 with systemic therapies. He is frequently consulted for complex prostate cancer cases and regularly shapes national guidelines.